Interferon for hepatitis C virus in hemodialysis - An individual patient meta-analysis of factors associated with sustained virological response

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 9, 2009, Pages 1449-1458

  Gordon, Craig E ^a   Uhlig, Katrin ^a   Lau, Joseph ^a   Schmid, Christopher H ^a   Levey, Andrew S ^a   Wong, John B ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON; VIRUS RNA;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MEDLINE; META ANALYSIS; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; RENAL DIALYSIS; RNA, VIRAL; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 73249150359     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01850309     Document Type: Article

References (48)

1. World Health Organization: Weekly Epidemiological Record 1999;49: 10, December 1999
2. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW: Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 65: 2335-2342, 2004
3. Huraib S, al-Rashed R, Aldrees A, Aljefry M, Arif M, al-Faleh FA: High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: A need for new dialysis strategies. Nephrol Dial Transplant 10: 470-474, 1995
4. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G: Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 20: 1271-1277, 2004
5. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S: Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 18: 1584-1593, 2007
6. Watanabe H, Saito T, Shinzawa H, Okumoto K, Hattori E, Adachi T, Takeda T, Sugahara K, Ito JI, Saito K, Togashi H, Suzuki R, Hayashi M, Miyamura T, Matsuura Y, Kawata S: Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population-based cohort study. J Med Virol 71: 56-61, 2003
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492, 1998
8. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352: 1426-1432, 1998
9. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, Hopf U: Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 32: 835-841, 2000
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958-965, 2001
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002
12. Kokoglu OF, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese MA, Isik IO: Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 21: 575-580, 2006
13. Russo MW, Ghalib R, Sigal S, Joshi V: Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21: 437-443, 2006
14. Sporea I, Popescu A, Sirli R, Golea O, Totolici C, Danila M, Vernic C: Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 12: 4191-4194, 2006
15. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R: Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. Journal of Viral Hepatitis 13: 316-321, 2006
16. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Kao JH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS: Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: A randomised study. Gut 57: 525-530, 2008
17. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT: Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. The International Journal of Artificial Organs 31: 295-302, 2008
18. Ucmak H, Kokoglu OF, Hosoglu S, Dogan E, Sayarlioglu H, Kuzhan N, Isik IO: Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients. Renal Failure 30: 227-232, 2008
19. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59: 1426-1431, 1995
20. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D: Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 74: 512-516, 1996
21. Kidney disease: Improving global outcomes (KDIGO) Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int 73 [Suppl 109]: S1-S99, 2008
22. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB: Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: A systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 51: 263-277, 2008
23. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38: 645-652, 2003
24. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Chaneac M, Reddy KR: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43: 425-433, 2005
25. Russo MW, Goldsweig CD, Jacobson IM, Brown RS, Jr.: Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 98: 1610-1615, 2003
26. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P: Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 18: 1071-1081, 2003
27. Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, Casellas J, Pons M, de Las Cuevas X, Piera J, Oliva JA, Costa J, Barrera JM, Bruguera M: Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 14: 2704-2709, 1999
28. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Perez JL, Guerrero L, Gonzalez MT, Andres E, Gil-Vernet S, Casais LA: Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: Results after transplantation. Am J Gastroenterol 96: 1170-1177, 2001
29. Buargub M, El Huni S, Tagdi M: Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi J Kidney Dis Transpl 17: 338-343, 2006
30. Huraib S, Iqbal A, Tanimu D, Abdullah A: Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 21: 435-440, 2001
31. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L: Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14: 2092-2098, 2003
32. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT, Payen JL, Duffaut M, Durand D, Suc JM, Puel J: High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 176: 1614-1617, 1997
33. Espinosa M, Rodriguez M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Lopez-Rubio F, de la Mata M, Aljama P: Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 55: 220-226, 2001
34. Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, Diebold MD, Wynckel A, Chanard J: Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 88: 120-126, 2001
35. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA: Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 36: 1831-1834, 2004
36. Okuda K, Hayashi H, Yokozeki K, Kondo T, Kashima T, Irie Y: Interferon treatment for chronic hepatitis C in haemodialysis patients: Suggestions based on a small series. J Gastroenterol Hepatol 10: 616-620, 1995
37. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Brechot C: Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 47: 1412-1418, 1995
38. Ozdemir FN, Akcay A, Sezer S, Boyacioglu S, Ozdemir BH, Arat Z, Haberal M: A six-year follow-up after interferonalpha monotherapy for chronic hepatitis C infection in hemodialysis patients. Ren Fail 26: 583-588, 2004
39. Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K, Neyer U, Stummvoll HK, Gruenewald K: Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 45: 1507-1509, 1994
40. Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, Pestana JO, Lanzoni VP, Silva AE, Ferraz ML: Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 26: 305-310, 2006
41. Chan TM, Wu PC, Lau JY, Lok AS, Lai CL, Cheng IK: Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 12: 1414-1419, 1997
42. Raptopoulou-Gigi M, Spaia S, Garifallos A, Xenou P, Orphanou H, Zarafidou E, Petridou P, Vrettou H, Vagionas G, Galaktidou G, Mavroudi I, Efkarpidou A, Kortsaris A: Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 10: 1834-1837, 1995
43. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, Carnot F, Riffaud PC, Chevret S: The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol Dial Transplant 16: 1017-1023, 2001
44. Huraib S, Tanimu D, Romeh SA, Quadri K, Al Ghamdi G, Iqbal A, Abdulla A: Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 34: 55-60, 1999
45. Benci A, Caremani M, Menchetti D, Sasdelli M, Giusti PB: Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Curr Med Res Opin 14: 141-144, 1998
46. Fernandez JL, Rendo P, del Pino N, Viola L: A doubleblind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. J Viral Hepat 4: 113-119, 1997
47. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49: 1335-1374, 2009
48. van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC: Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 23: 721-725, 2008